Substituted Indole Dimer Compounds for TLR Inhibition
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases related to Toll-like receptor 7, 8, and 9 (TLR7, TLR8, TLR9) modulation are inadequate, as existing therapies fail to effectively inhibit sustained aberrant activation of these receptors, leading to worsening disease states in autoimmune disorders.
Innovation Solution
Development of substituted indole dimer compounds that act as inhibitors of signaling through TLR7, TLR8, and TLR9, providing pharmaceutical compositions and methods for their use in treating proliferative, allergic, autoimmune, and inflammatory diseases by administering therapeutically effective amounts of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat inflammatory and autoimmune diseases, then treatment is provided, but the therapies fail to effectively inhibit sustained aberrant activation of TLR7, TLR8, and TLR9, leading to worsening disease states
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (substituted indole dimers with particular substituent patterns at positions 1, 2, 3, 4, 5, 6, 7) that optimize TLR7/8/9 binding affinity and inhibition efficacy. The systematic variation of substituent groups (R1-R6) allows tuning of pharmacological properties to achieve reliable TLR inhibition and prevent disease worsening
Solution Approach 2:
The invention uses composite molecular structures combining indole dimer cores with various substituent groups to create compounds that simultaneously achieve multiple objectives: high TLR inhibition efficacy, appropriate pharmacokinetic properties, and selective activity against TLR7/8/9. The composite nature of these molecules enables them to effectively address the harmful aberrant TLR activation
2Reliability
If new substituted indole dimer compounds are developed to inhibit TLR7/8/9 signaling, then therapeutic benefits are achieved, but the compounds must be optimized for stability, bioavailability, and toxicity
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions: a core indole dimer framework and variable substituent groups (R1-R6) at specific positions. This segmentation allows independent optimization of each region's properties - the core provides structural stability while substituents tune pharmacokinetic and pharmacodynamic characteristics, simplifying the overall optimization process
Solution Approach 2:
The invention implements local quality by introducing specific substituent groups at defined positions (1, 2, 3, 4, 5, 6, 7) on the indole dimer core. Each substituent can be independently selected to provide local functional properties such as enhanced metabolic stability, improved membrane permeability, or reduced toxicity, while maintaining the overall therapeutic efficacy of the compound
Data Source
AI summary
Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.